Posted by Michael Wonder on 30 May 2023
US FDA approves Blue Earth Diagnostics’ Posluma (flotufolastat F 18) injection, first radiohybrid PSMA targeted PET imaging agent for prostate cancer
30 May 2023 - Posluma will be commercially available in the United States in early June 2023.
Blue Earth Diagnostics today announced US FDA approval for its optimised, high-affinity radiohybrid prostate specific membrane antigen targeted PET imaging agent, Posluma (flotufolastat F 18) injection (formerly referred to as 18F-rhPSMA-7.3).
